Comparison of rituximab vs. cyclophosphamide in rheumatoid arthritis-associated interstitial lung disease and its correlation with spirometry
Introduction: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a significant health concern affecting a substantial population in India. This study outlines the limitations of current treatment options. Specifically, the toxicity of cyclophosphamide sets the stage for investigat...
Saved in:
Main Authors: | Mohammed Abdullah Saleem, Atiya Parveen, Fazeel Zubair Ahmed |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2024-12-01
|
Series: | The Journal of Association of Chest Physicians |
Subjects: | |
Online Access: | https://journals.lww.com/10.4103/jacp.jacp_28_24 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Janus kinase inhibitors in rheumatoid arthritis-associated interstitial lung disease: where do we stand and what may be the future?
by: Beatrice Maranini, et al.
Published: (2025-01-01) -
Fibroblasts in rheumatoid arthritis: novel roles in joint inflammation and beyond
by: Elpida Neofotistou-Themeli, et al.
Published: (2025-01-01) -
Warrick score in rheumatoid-arthritis interstitial lung disease: a promising tool for assessing the extent and progression of lung involvement
by: Duygu Temiz Karadag, et al.
Published: (2025-01-01) -
Expert Panel consensus statements on the optimal usage of rituximab for the management of rheumatoid arthritis in India
by: Keerthi Talari, et al.
Published: (2021-01-01) -
Osthole regulates N6‐methyladenosine‐modified TGM2 to inhibit the progression of rheumatoid arthritis and associated interstitial lung disease
by: Xian Lin, et al.
Published: (2023-04-01)